Navigation Links
MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
Date:5/6/2008

GAITHERSBURG, Md., May 6 /PRNewswire/ -- MedImmune today announced that it has enhanced its leadership team to guide the company's expanded product pipeline in the United States and abroad as well as the core scientific research that underpins this development. Jacqueline Hall has been appointed global vice president, product development team leadership; Lorin Roskos, Ph.D. has been appointed vice president and global head of pharmacokinetics (PK), pharmacodynamics (PD), and bioanalysis in translational sciences and Beth Wensley has been appointed vice president, project management. In addition, Erik-Jan Dekker, Ph.D. joined the organization as vice president, international regulatory affairs, vaccines and Reginald Seeto, M.D., joins as vice president, global strategic marketing and portfolio management.

"It is imperative that we have strong leaders who can channel the continued growth of our product portfolio, particularly as we seek to build out the organization globally," said David M. Mott, chief executive officer and president. "Jacqui, Lorin, Beth, E-J and Reg have the innate talent, industry experience and drive for results that will contribute to MedImmune's continued leadership in biologics."

Based at MedImmune's Cambridge, UK site, Ms. Jacqueline Hall is accountable for the strategic leadership of global product development teams that are responsible for the generation and execution of development plans for biologics products. She joined Cambridge Antibody Technology (CAT), now MedImmune, in 2006 as vice president, project management. Previously, Ms. Hall served as project leader at GlaxoSmithKline where she was responsible for the strategic development of product candidates from selection through to market launch. She has also held positions at SmithKline Beecham, Pharmaco-LSR and Schering-Plough. Ms. Hall has a first-class honors degree in chemistry from Imperial College of Science and Technology/Birbeck College, London and a diploma in clinical science from the Welsh School of Pharmacy, Cardiff.

Dr. Lorin Roskos is responsible for managing and integrating preclinical and clinical PK/PD and bioanalytical groups at MedImmune sites in Maryland, California and England. Dr. Roskos became part of the MedImmune team in 2008 after a year at AstraZeneca as executive director of research and development. Prior to AstraZeneca, Dr. Roskos spent six years at Abgenix, Inc., as the head of PK and toxicology, and has prior experience in PK and drug metabolism at Amgen and Eli Lilly. He holds a doctorate in pharmaceutics from the University of Washington and a bachelor's degree in biochemistry and pharmacy from the University of Georgia.

Ms. Beth Wensley oversees the global project management team that provides strategic project management in driving forward the product development teams and the overall product development portfolio. Ms. Wensley joined MedImmune in 2001, and has previously served as senior director, California operations; director, supply chain operations; and associate director, project management. She earned extensive project management, operational, manufacturing and environmental, health & safety experience during her tenure with companies such as Incyte Genomics, Raychem Corporation and Syntex Pharmaceuticals. She holds a master's degree in business administration from Santa Clara University and a master's in environmental science from the University of Washington. She also has a bachelor's degree in biology from California Lutheran College and is APICS certified from the Association for Operations Management.

Based in the Netherlands as MedImmune's new vice president, international regulatory affairs, vaccines, Dr. Erik-Jan Dekker is leveraging his 17 years' experience in regulatory affairs to lead MedImmune's expansion overseas. In his previous position at Baxter Healthcare, he was the global senior director, regulatory affairs, biologics, responsible for worldwide vaccine and biosurgery marketing authorization applications. Prior to joining Baxter Healthcare, Dr. Dekker was the director of regulatory affairs globally at Laboratoire Francais du Fractionnement et des Biotechnologies in France. Earlier in his career, Dr. Dekker held teaching positions at the University of Utrecht and Alkwin College. From the University of Utrecht, Dr. Dekker holds a doctorate in biochemistry and molecular developmental biology and genetics, a master's degree in biology and international patent law and a bachelor's degree in biology and geography.

As MedImmune's new vice president, global strategic marketing and portfolio management, Dr. Reginald Seeto is responsible for providing strategic guidance on investment decisions and managing commercialization efforts for new products in various stages of development. In his previous position at Organon International, he was the vice president of global marketing, fertility, immunology, oncology and vaccines. Previously, Dr. Seeto was the executive director of marketing at Boehringer Ingelheim Pharmaceuticals and had served as an engagement manager at McKinsey & Company. He holds both a medical degree and a bachelor of science degree from the University of Sydney, and practiced medicine in Australia early in his career.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
2. Seneca Valley High School Student Receives Science Award From MedImmune
3. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
4. MedImmune Submits Biologics License Application to FDA for Motavizumab
5. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
6. MedImmune Announces Seven Key Promotions and New Hires
7. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
8. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
9. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
10. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):